Search results
22 maj 2023 · Objectives: Outline the typical presentation of a patient with bullous systemic lupus erythematosus. Describe the histopathology and immunopathology of bullous systemic lupus erythematosus. Summarize management options available for bullous systemic lupus erythematosus.
6 paź 2017 · The aim of this guideline was to produce recommendations for the management of adult lupus patients in the UK that cover the diagnosis, assessment and monitoring of lupus and the treatment of mild, moderate and severe active lupus disease, but which do not imply a legal obligation.
BSR's 'gold standard' clinical guidelines support evidence-based clinical practice in rheumatology. Our guidelines are developed using the methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol and overseen by our Guidelines Steering Group.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
7 paź 2021 · Pharmacologic Therapy. Dapsone is the initial treatment of choice for bullous systemic lupus erythematosus. [2, 34] The response is usually dramatic, with cessation of new blister formation...
26 paź 2023 · In clinical science, the summary includes updates in diagnosis and classification, clinical features and subphenotypes, and current guidelines and strategies for treatment. The paper also provides a comprehensive review of the large number of recent clinical trials in systemic lupus erythematosus.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [ 1 – 3 ].
